IQVIA Reports Fourth-Quarter and Full-Year 2018 Results, Issues First-Quarter and Full-Year 2019 Guidance

  • Revenue of $2,688 million for the fourth quarter and $10,412
    million for the full year
  • Adjusted EBITDA of $583 million for the fourth quarter and $2,224
    million for the full year
  • GAAP Diluted Earnings per Share of $0.34 for the fourth quarter and
    $1.24 for the full year
  • Adjusted Diluted Earnings per Share of $1.50 for the fourth quarter
    and $5.55 for the full year
  • Record quarter of R&D Solutions contracted services Net New
    Business, resulting in a book-to-bill ratio of 1.7x for the quarter
  • Full-year contracted services Net New Business growth of 28.9
    percent, contributing to total backlog of over $17.1 billion
  • $604 million of share repurchase completed during the fourth
    quarter; $1.4 billion of share repurchase completed in 2018;
    authorization increased by $2.0 billion
  • Full-year 2019 revenue guidance of $10,900 million to $11,125
    million, Adjusted EBITDA of $2,375 million to $2,425 million and
    Adjusted Diluted Earnings per Share of $6.20 to $6.40

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of
advanced analytics, technology solutions, and contract research services
to the life sciences industry, today reported financial results for the
quarter and year ended December 31, 2018.

On January 1, 2018, IQVIA adopted ASC 606 “Revenue from Contracts with
Customers” as required by the Financial Accounting Standards Board.
Under this standard, IQVIA recognizes revenue in the Research &
Development Solutions segment on a percentage of completion basis.
Additionally, ASC 606 requires that service revenue and reimbursed
expense revenue be consistently presented as one line on the income
statement. Unless stated otherwise, all financial information that
follows has been provided under ASC 606.

This will be the last reminder of the accounting change, as following
the fourth quarter, IQVIA has passed the anniversary of ASC 606
adoption, which will be the basis for all reporting going forward.

Fourth-Quarter 2018 Operating Results
Revenue for the fourth
quarter of $2,688 million increased 6.6 percent on a reported basis and
8.1 percent at constant currency, compared to the fourth quarter of
2017. Technology & Analytics Solutions (TAS) revenue of $1,127 million
grew 8.8 percent reported and 10.9 percent at constant currency.
Research & Development Solutions (R&DS) revenue of $1,368 million grew
7.8 percent reported and 8.7 percent at constant currency. Contract
Sales & Medical Solutions (CSMS) revenue of $193 million declined 10.6
percent reported and 8.8 percent at constant currency.

Fourth-quarter 2018 Adjusted EBITDA of $583 million increased 10.8
percent reported and 9.7 percent at constant currency, compared to the
fourth quarter of 2017. GAAP net income was $69 million and GAAP diluted
earnings per share was $0.34. Adjusted Net Income of $307 million grew
17.6 percent, and Adjusted Diluted Earnings per Share of $1.50 grew 23.0
percent.

“We closed 2018 with a strong quarter, and delivered results at the high
end of, or above our financial targets, capping a year of outstanding
performance,” said Ari Bousbib, chairman and CEO of IQVIA. “Our clinical
development team had another record quarter of contracted net new
business, and our technology team continued to add impressive new client
wins for our OCE SaaS platform. As we enter the third year of our merger
integration, we are pleased to see the beginning of top line
acceleration in both our R&DS and TAS businesses. We are also encouraged
that our CSMS business is showing positive signs of stabilization as we
head into 2019. Across all our businesses, the IQVIA team is building
momentum to further accelerate growth beyond 2019.”

Full-Year 2018 Operating Results
Revenue of $10,412 million
for the full year of 2018 increased 7.3 percent reported and 6.8 percent
at constant currency, compared to the full year of 2017. TAS revenue of
$4,137 million grew 12.4 percent reported and 12.1 percent at constant
currency. R&DS revenue of $5,465 million grew 7.1 percent reported and
6.5 percent at constant currency. CSMS revenue of $810 million declined
11.5 percent reported and 12.2 percent at constant currency.

R&DS contracted backlog, including reimbursed expenses, was $17.13
billion at December 31, 2018. The company expects approximately $4.8
billion of this backlog to convert to revenue in the next twelve months.
For comparability during 2018, IQVIA is reporting R&DS net new business
on a contracted basis excluding reimbursed expenses. Under this
approach, R&DS contracted net new business of $5.85 billion for the
twelve months ended December 31, 2018 grew 28.9 percent compared to the
twelve months ended December 31, 2017. R&DS contracted net new business
for the quarter ending December 31, 2018 was $1.7 billion, representing
a contracted book-to-bill ratio (excluding reimbursed expenses) of 1.7x
for the fourth quarter of 2018.

For the full year of 2018, Adjusted EBITDA of $2,224 million increased
10.6 percent reported and 9.9 percent at constant currency, compared to
the full year of 2017. GAAP net income was $259 million and GAAP diluted
earnings per share was $1.24. Adjusted Net Income of $1,156 million for
the full year of 2018 grew 14.0 percent, and Adjusted Diluted Earnings
per Share of $5.55 grew 22.0 percent.

Financial Position
As of December 31, 2018, cash and cash
equivalents were $891 million and debt was $11,007 million, resulting in
net debt of $10,116 million. At the end of the fourth quarter of 2018,
IQVIA’s Gross Leverage Ratio was 4.9 times, and Net Leverage Ratio was
4.5 times, trailing twelve month Adjusted EBITDA.

Share Repurchase
The company repurchased $604 million of its
common stock during the fourth quarter of 2018, including a repurchase
of $247 million from IQVIA’s remaining private equity sponsors towards
the end of the quarter. Full-year 2018 share repurchases totaled $1.4
billion.

On February 13, 2019, the IQVIA board approved an increase of the share
repurchase authorization by $2.0 billion, bringing remaining
authorizations to approximately $2.3 billion.

Full-Year 2019 Guidance
IQVIA expects full-year 2019 revenue
between $10,900 million and $11,125 million, Adjusted EBITDA between
$2,375 million and $2,425 million and Adjusted Diluted Earnings per
Share between $6.20 and $6.40. Full-year 2019 segment revenue guidance
is as follows:

     
($ millions)   Guidance (1)   VPY% CFx (1)   VPY% AFx (1)
TAS $4,350 – $4,425 6.7% – 8.6%

5.1% – 7.0%

R&DS $5,750 – $5,900 6.0% – 8.8% 5.2% – 8.0%
CSMS

~$800

~flat

~(1.2)%

Revenue   $10,900 – $11,125   5.8% – 7.9%   4.7% – 6.8%

1. Guidance dollars are at actual foreign currency
exchange rates. CFx is constant currency, AFx is actual currency.

 

First-Quarter 2019 Guidance
IQVIA expects first-quarter 2019
revenue between $2,630 million and $2,680 million, Adjusted EBITDA
between $575 million and $590 million and Adjusted Diluted Earnings per
Share between $1.48 and $1.53.

This financial guidance assumes foreign currency exchange rates at
January 1, 2019 remain in effect for the remainder of the year.

Webcast & Conference Call Details
IQVIA will host a
conference call at 9:00 a.m. Eastern Time today to discuss its fourth
quarter and full year 2018 financial results and 2019 guidance. To
participate, please dial 1-800-919-0370 in the United States and Canada
or +1-212-231-2935 outside the United States approximately 15 minutes
before the scheduled start of the call. The conference call and a
presentation will be accessible live via webcast on the Investors
section of the IQVIA website at http://ir.iqvia.com.
An archived replay of the webcast will be available online at http://ir.iqvia.com
after 1:00 p.m. Eastern Time today.

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of
advanced analytics, technology solutions and contract research services
to the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding scope
of human science — to enable companies to reimagine and develop new
approaches to clinical development and commercialization, speed
innovation and accelerate improvements in healthcare outcomes. Powered
by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the
intersection of large-scale analytics, transformative technology and
extensive domain expertise, as well as execution capabilities. With more
than 58,000 employees, IQVIA conducts operations in more than 100
countries.

Cautionary Statements Regarding Forward-Looking Statements
This
press release contains “forward-looking statements” within the meaning
of the federal securities laws, including Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including, without limitation, our 2019 guidance.
In this context, forward-looking statements often address expected
future business and financial performance and financial condition, and
often contain words such as “expect,” “anticipate,” “intend,” “plan,”
“believe,” “seek,” “see,” “will,” “would,” “target,” similar
expressions, and variations or negatives of these words. Actual results
may differ materially from our expectations due to a number of factors,
including, but not limited to, the following: most of our contracts may
be terminated on short notice, and we may lose or experience delays with
large client contracts or be unable to enter into new contracts;
imposition of restrictions on our use of data by data suppliers or their
refusal to license data to us; any failure by us to comply with
contractual, regulatory or ethical requirements under our contracts,
including current or changes to data protection and privacy laws;
breaches or misuse of our or our outsourcing partners’ security or
communications systems; hardware and software failures, delays in the
operation of our computer and communications systems or the failure to
implement system enhancements; failure to meet our productivity or
business transformation objectives; failure to successfully invest in
growth opportunities; our ability to protect our intellectual property
rights and our susceptibility to claims by others that we are infringing
on their intellectual property rights; the expiration or inability to
acquire third party licenses for technology or intellectual property;
any failure by us to accurately and timely price and formulate cost
estimates for contracts, or to document change orders; the rate at which
our backlog converts to revenue; our ability to acquire, develop and
implement technology necessary for our business; consolidation in the
industries in which our clients operate; risks related to client or
therapeutic concentration; the risks associated with operating on a
global basis, including currency or exchange rate fluctuations and legal
compliance, including anti-corruption laws; risks related to changes in
accounting standards, including the impact of the changes to the revenue
recognition standards; general economic conditions in the markets in
which we operate, including financial market conditions and risks
related to sales to government entities; the impact of changes in tax
laws and regulations; and our ability to successfully integrate, and
achieve expected benefits from, our acquired businesses. For a further
discussion of the risks relating to the combined company’s business, see
the “Risk Factors” in our annual report on Form 10-K for the fiscal year
ended December 31, 2017, filed with the SEC, as such factors may be
amended or updated from time to time in our subsequent periodic and
other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.
These factors should not be construed as exhaustive and should be read
in conjunction with the other cautionary statements that are included in
this release and in our filings with the SEC. We assume no obligation to
update any such forward-looking statement after the date of this
release, whether as a result of new information, future developments or
otherwise.

Note on Non-GAAP Financial Measures
Non-GAAP results, such
as Adjusted EBITDA, Adjusted Net Income, and Adjusted Diluted EPS are
presented only as a supplement to the company’s financial statements
based on GAAP. Non-GAAP financial information is provided to enhance
understanding of the company’s financial performance, but none of these
non-GAAP financial measures are recognized terms under GAAP, and
non-GAAP measures should not be considered in isolation from, or as a
substitute analysis for, the company’s results of operations as
determined in accordance with GAAP. Definitions and reconciliations of
non-GAAP measures to the most directly comparable GAAP measures are
provided within the schedules attached to this release. The company uses
non-GAAP measures in its operational and financial decision making, and
believes that it is useful to exclude certain items in order to focus on
what it regards to be a more meaningful indicator of the underlying
operating performance of the business. As a result, internal management
reports feature non-GAAP measures which are also used to prepare
strategic plans and annual budgets and review management compensation.
The company also believes that investors may find non-GAAP financial
measures useful for the same reasons, although investors are cautioned
that non-GAAP financial measures are not a substitute for GAAP
disclosures.

Our 2019 guidance measures (other than revenue) are provided on a
non-GAAP basis because the company is unable to reasonably predict
certain items contained in the GAAP measures. Such items include, but
are not limited to, acquisition and integration related expenses,
restructuring and related charges, stock-based compensation and other
items not reflective of the company’s ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors
and other interested parties in their evaluation of companies comparable
to the company, many of which present non-GAAP measures when reporting
their results. Non-GAAP measures have limitations as an analytical tool.
They are not presentations made in accordance with GAAP, are not
measures of financial condition or liquidity and should not be
considered as an alternative to profit or loss for the period determined
in accordance with GAAP or operating cash flows determined in accordance
with GAAP. Non-GAAP measures are not necessarily comparable to similarly
titled measures used by other companies. As a result, you should not
consider such performance measures in isolation from, or as a substitute
analysis for, the company’s results of operations as determined in
accordance with GAAP.

Click
here to subscribe to Mobile Alerts for IQVIA.

IQVIAFIN

       
Table 1
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(in millions, except per share data)
(preliminary and unaudited)
 
 
Three Months Ended Year Ended
December 31, December 31,
  2018 2017 2018 2017
Revenues $ 2,688 $ 2,521 $ 10,412 $ 9,702
Costs of revenue, exclusive of depreciation and amortization 1,742 1,607 6,746 6,301
Selling, general and administrative expenses 443 469 1,716 1,622
Depreciation and amortization 294 278 1,141 1,011
Impairment charges 40
Restructuring costs   2     25     68     63  
Income from operations 207 142 741 665
Interest income (3 ) (2 ) (8 ) (7 )
Interest expense 106 97 414 346
Loss on extinguishment of debt (2 ) 2 19
Other expense, net       16     5     13  

Income before income taxes and equity in earnings of
unconsolidated affiliates

104 33 328 294
Income tax expense (benefit)   30     (999 )   59     (992 )

Income before equity in earnings of unconsolidated affiliates

74 1,032 269 1,286
Equity in earnings of unconsolidated affiliates   2     3     15     10  
Net income 76 1,035 284 1,296
Net income attributable to non-controlling interests   (7 )   (8 )   (25 )   (19 )
Net income attributable to IQVIA Holdings Inc. $ 69   $ 1,027   $ 259   $ 1,277  
Earnings per share attributable to common stockholders:
Basic $ 0.34 $ 4.91 $ 1.27 $ 5.86
Diluted $ 0.34 $ 4.79 $ 1.24 $ 5.74
Weighted average common shares outstanding:
Basic 199.5 209.3 203.7 217.8
Diluted 204.1 214.2 208.2 222.6
 
   
Table 2
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in millions, except per share data)
(preliminary and unaudited)
 
 
December 31,
  2018 2017
ASSETS
Current assets:
Cash and cash equivalents $ 891 $ 959
Trade accounts receivable and unbilled services, net 2,394 2,097
Prepaid expenses 151 146
Income taxes receivable 69 47
Investments in debt, equity and other securities 47 46
Other current assets and receivables   322     259  
Total current assets   3,874     3,554  
Property and equipment, net 434 440
Investments in debt, equity and other securities 41 8
Investments in unconsolidated affiliates 101 70
Goodwill 11,800 11,850
Other identifiable intangibles, net 5,951 6,591
Deferred income taxes 109 109
Deposits and other assets   239     235  
Total assets $ 22,549   $ 22,857  
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 437 $ 322
Accrued expenses 1,858 1,664
Unearned income 1,007 985
Income taxes payable 100 72
Current portion of long-term debt 100 103
Other current liabilities   32     10  
Total current liabilities 3,534 3,156
Long-term debt, less current portion 10,907 10,122
Deferred income taxes 736 895
Other liabilities   418     440  
Total liabilities   15,595     14,613  
Commitments and contingencies
Stockholders’ equity:

Common stock and additional paid-in capital,

400.0 shares authorized at December 31, 2018 and 2017,

$0.01 par value,251.5 and 249.5 shares issued at December 31, 2018

and 2017, respectively

10,901 10,782
Retained earnings 807 538

Treasury stock, at cost, 54.0 and 41.4 shares at December 31, 2018

and 2017, respectively

(4,770 ) (3,374 )
Accumulated other comprehensive (loss) income   (224 )   49  
Equity attributable to IQVIA Holdings Inc.’s stockholders 6,714 7,995
Non-controlling interests   240     249  
Total stockholders’ equity   6,954     8,244  
Total liabilities and stockholders’ equity $ 22,549   $ 22,857  
 
   
Table 3
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(preliminary and unaudited)
 
 
Year Ended
December 31,
  2018 2017
Operating activities:
Net income $ 284 $ 1,296
Adjustments to reconcile net income to cash provided by operating
activities:
Depreciation and amortization 1,141 1,011
Amortization of debt issuance costs and discount 11 9

Amortization of accumulated other comprehensive loss

on terminated interest rate swaps

3
Stock-based compensation 113 106
Impairment of goodwill and identifiable intangible assets 40
Gain on disposals of property and equipment, net (1 )
Earnings from unconsolidated affiliates (15 ) (10 )
Loss (gain) on investments, net 3 (8 )
Benefit from deferred income taxes (177 ) (1,221 )
Changes in operating assets and liabilities:
Accounts receivable and unbilled services (297 ) (141 )
Prepaid expenses and other assets (66 ) (54 )
Accounts payable and accrued expenses 368 90
Unearned income 7 (68 )
Income taxes payable and other liabilities   (118 )   (82 )
Net cash provided by operating activities 1,254 970
Investing activities:
Acquisition of property, equipment and software (459 ) (369 )
Acquisition of businesses, net of cash acquired (309 ) (854 )
Disposition of business, net of cash disposed 12
(Purchases) sales of marketable securities (4 ) 2
Investments in unconsolidated affiliates, net of payments received (17 ) 15
Investments in equity securities (23 )
Other   2     4  
Net cash used in investing activities (810 ) (1,190 )
Financing activities:
Proceeds from issuance of debt 1,631 5,242
Payment of debt issuance costs (22 ) (50 )
Repayment of debt (732 ) (2,883 )
Proceeds from revolving credit facility 2,445 1,921
Repayment of revolving credit facility (2,329 ) (1,767 )
Principal payments on capital lease obligations (2 )
Proceeds related to employee stock option plans 15 91
Repurchase of common stock (1,405 ) (2,620 )
Distributions to non-controlling interests, net (31 )
Contingent consideration and deferred purchase price payments   (24 )   (4 )

Net cash used in financing activities

(452 ) (72 )
Effect of foreign currency exchange rate changes on cash   (60 )   53  
Decrease in cash and cash equivalents (68 ) (239 )
Cash and cash equivalents at beginning of period   959     1,198  
Cash and cash equivalents at end of period $ 891   $ 959  
 

 
Table 4
IQVIA HOLDINGS INC. AND SUBSIDIARIES
NET INCOME TO ADJUSTED EBITDA RECONCILIATION
(in millions)
(preliminary and unaudited)
       
 
Three Months Ended Year Ended
December 31, December 31,
  2018 2017 2018 2017
Net Income Attributable to IQVIA Holdings Inc. $ 69 $ 1,027 $ 259 $ 1,277
Provision for (benefit from) income taxes 30 (999 ) 59 (992 )
Depreciation and amortization 294 278 1,141 1,011
Interest expense, net 103 95 406 339
Income in unconsolidated affiliates (2 ) (3 ) (15 ) (10 )
Income from non-controlling interests 7 8 25 19
Deferred revenue purchasing accounting adjustments 1 5 7 15
Stock-based compensation 35 24 113 106
Other expense, net 22 27 37
(Gain) loss on extinguishment of debt (2 ) 2 19
Impairment charges 40
Restructuring and related charges 2 25 68 63
Acquisition related charges 12 17 50 44
Integration related costs   32     29     82     42  
Adjusted EBITDA $ 583   $ 526   $ 2,224   $ 2,010  
 

Note: Numbers may not add to total due to rounding.

 

 
Table 5
IQVIA HOLDINGS INC. AND SUBSIDIARIES
NET INCOME TO ADJUSTED NET INCOME RECONCILIATION
(in millions, except per share data)
(preliminary and unaudited)
       
Three Months Ended Year Ended
December 31, December 31,
  2018 2017 2018 2017
Net Income Attributable to IQVIA Holdings Inc. $ 69 $ 1,027 $ 259 $ 1,277
Provision for (benefit from) income taxes 30 (999 ) 59 (992 )
Purchase accounting amortization 212 217 863 770
Income in unconsolidated affiliates (2 ) (3 ) (15 ) (10 )
Income from non-controlling interests 7 8 25 19
Deferred revenue purchasing accounting adjustments 1 5 7 15
Stock-based compensation 35 24 113 106
Other expense, net 22 27 37
(Gain) loss on extinguishment of debt (2 ) 2 19
Impairment charges 40
Royalty hedge gain 2 8
Restructuring and related charges 2 25 68 63
Acquisition related charges 12 17 50 44
Integration related costs   32     29     82     42  
Adjusted Pre Tax Income $ 400 $ 369 $ 1,540 $ 1,437
Adjusted tax expense (84 ) (98 ) (350 ) (395 )
Income from non-controlling interests (7 ) (8 ) (25 ) (19 )
Minority interest effect in non-GAAP adjustments (1)   (2 )   (4 )   (9 )   (11 )
Adjusted Net Income $ 307   $ 261   $ 1,156   $ 1,014  
 
Adjusted earnings per share attributable to common stockholders:
Basic $ 1.54 $ 1.25 $ 5.68 $ 4.66
Diluted $ 1.50 $ 1.22 $ 5.55 $ 4.55
Weighted-average common shares outstanding:
Basic 199.5 209.3 203.7 217.8
Diluted 204.1 214.2 208.2 222.6
 

(1) Reflects the portion of Q2 Solutions’ after-tax non-GAAP
adjustments attributable to the minority interest partner.

Note:  Numbers may not add to total due to rounding.

 

 
Table 6
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CALCULATION OF GROSS AND NET LEVERAGE RATIOS
AS OF DECEMBER 31, 2018
(in millions)
(preliminary and unaudited)
 
 
   
Gross Debt, net of Original Issue Discount, as of December 31, 2018 $ 11,007
Net Debt as of December 31, 2018 $ 10,116  
Adjusted EBITDA for the year ended December 31, 2018 $ 2,224  
Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA)

4.9

x

Net Leverage Ratio (Net Debt/LTM Adjusted EBITDA)

4.5

x

Contacts

Andrew Markwick, IQVIA Investor Relations ([email protected])
+1.973.257.7144

Tor
Constantino, IQVIA Media Relations ([email protected])
+1.484.567.6732

error: Content is protected !!